These results suggest that the increased level of LAT1 contributes to hormone-refractory prostate cancer and LAT1 may be a feasible target for the treatment of advanced prostate cancer (Wang et al., 2011, 2013). This evidence concerns the gene SLC7A5 and prostate carcinoma.